Armis Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$276K Buy
522
+27
+5% +$12K 0.03% 383
2026
Q1
$224K Buy
+495
New +$231K 0.02% 415
2025
Q1
Sell
-892
Closed -$359K 464
2024
Q4
$359K Buy
+892
New +$413K 0.04% 233

Other funds holding VRTX

Armis Advisers's VRTX Position: Q2 2026 in Review

Armis Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 5.5% in Q2 2026, buying an estimated $12K and bringing the position to 522 shares worth $276K. The position accounts for 0.03% of the portfolio, ranked #383.

Armis Advisers first reported a position in VRTX in Q4 2024 and has held it in 3 quarters since. The position peaked at $359K in Q4 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Armis Advisers held 522 shares of Vertex Pharmaceuticals worth $276K as of Q2 2026.
  • Armis Advisers bought 27 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12K.
  • Vertex Pharmaceuticals made up 0.03% of Armis Advisers's portfolio in Q2 2026, its #383 holding.
  • Armis Advisers first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • Armis Advisers's Vertex Pharmaceuticals position peaked at $359K in Q4 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Armis Advisers's 13F filing for Q2 2026, filed 7 Jul 2026.